Navigation Links
InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
Date:2/25/2008

LOS ALTOS, Calif., Feb. 25 /PRNewswire/ -- InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced today that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator). INT131 was the result of an extensive molecular design effort to address the product profile deficiencies of current TZD therapy, which while efficacious present problematic safety concerns. INT131 was selected specifically for its ability to reduce characteristic TZD adverse effects while retaining powerful PPAR anti-diabetic efficacy. This placebo controlled, double-blind, Phase 2b study includes multiple doses of orally administered INT131 once daily, and Actos(R) (pioglitazone) as an active comparator.

"INT131 has consistently demonstrated potent and selective PPAR-gamma modulation through each phase of development including recently completed primate safety studies, wherein an absence of recognized TZD adverse effects such as edema offers a genuine breakthrough for this target," said Linda Slanec Higgins, PhD, InteKrin's Chief Scientific Officer. "Preclinical safety multiples with INT131 are far greater than those seen with the currently marketed, first generation TZD full agonists."

"From a clinical perspective, insulin resistance is a key etiological feature in the onset and subsequent progression of Type 2 Diabetes, and it remains inadequately addressed by current therapies. INT131 has been demonstrated to be a potent and efficacious insulin sensitizer in humans and offers the opportunity for disease modification without the edema and weight gain of current TZD therapies," said Alex DePaoli, MD, InteKrin's Chief Medical Officer. "The initiation of this robust Phase 2b study represents an imp
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
5. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
6. ImaRx Therapeutics Transitions Business Strategy
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Boston Scientific Corporation (NYSE: BSX ... th Annual Global Healthcare Conference on June 9 in ... Dan Brennan , executive vice president and chief financial ... will participate in a 35-minute question and answer session regarding ... a.m. PT. A live webcast of the presentation ...
(Date:5/26/2015)... 26, 2015 Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... , President and Chief Executive Officer, will present at ... 2015 at 8:30 a.m. ET in New ... webcast of the presentation will be available on the ...
(Date:5/26/2015)... May 26, 2015  Northstar Global Business Services, ... solidified a deal with Mr. Checkout, a national ... anti-snoring product, SNORenz to brick and mortar retail ... a cross section of about fifty convenience stores, ... providing valuable statistics during the lead time the ...
Breaking Medicine Technology:Boston Scientific To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference 2Xencor to Present at Jefferies 2015 Healthcare Conference 2Northstar announces in-store rollout deal with national distribution group reaching more than 35,000 stores nationwide 2Northstar announces in-store rollout deal with national distribution group reaching more than 35,000 stores nationwide 3
... for clinical testing in human ... cancer ... issue, Cancer,Research published a peer-reviewed article from Genelux Corporation,describing successful eradication ... virus developed by Genelux scientists.,These promising results make a compelling case ...
... program to provide school-based support, and feminine hygiene products to girls in ... ... YORK, Nov. 12 Girls living in sub-Saharan,Africa can miss up to ... sanitary protection and other resources to manage their,periods. To help give girls ...
Cached Medicine Technology:Tumor Eradication Article Published by Cancer Research 2Tumor Eradication Article Published by Cancer Research 3Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School 2Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School 3Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School 4Tampax and Always Launch Protecting Futures Program Dedicated to Helping African Girls Stay in School 5
(Date:5/26/2015)... (PRWEB) May 26, 2015 Irwin Gross, ... and directed a hospital-wide Patient Blood Management (PBM) initiative ... reduced overall blood usage by more than 60 percent ... , Covered in detail in an article in the ... in substantially reduced perioperative red cell loss, less acute ...
(Date:5/26/2015)... Two addiction experts from Anaheim ... on a CNBC radio podcast for a “state ... KCAA AM 1050, the podcast features Tim Salyer, Anaheim ... as they discuss current statistics on drug and alcohol ... million Americans. The program, titled “Addiction, Self-Hatred, Hope and ...
(Date:5/26/2015)... 26, 2015 Synthetic cannabinoids attempt ... an article published by International Business Times ... K2, Spice, and black mamba) causes unpredictable medical ... synthetic substances make it nearly impossible for medical ... of the substance due to the frequency in ...
(Date:5/26/2015)... New Brunswick (PRWEB) May 26, 2015 ... announce the successful upgrade of the DMi Partners ... This version was the first in Indosoft's contact center ... API improvements, added screen support for such trunk features ... screens, improved lead management, and included upgrades to ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 i2i ... Analytics solutions for more than 15 years, has earned ... National Committee for Quality Assurance (NCQA) for its flagship ... “We are proud of the work we have done ... are grateful for the acknowledgement from NCQA once again,” ...
Breaking Medicine News(10 mins):Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 2Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 3Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3
... visually impaired, navigating city streets or neighborhoods has constant challenges. ... rudimentary technologya simple caneto help them make their way through ... California engineering researchers is working to change that by developing ... design first shown a year ago is now being further ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, May ... prescribed drugs, the antidepressant Paxil and the cholesterol-lowering medication ... new study finds. The increase is most apparent ... is already too high, the researchers noted. "This ...
... 2011) The Maryland Stem Cell Research Commission (Commission) ... in response to its three FY 2011 Requests for ... Technology Development Corporation (TEDCO) approved the Commission,s recommendation to ... Research Fund,s (MSCRF) $10.4 million FY 2011 budget. ...
... May 25 (HealthDay News) -- The Internet has put the ... also allowed banned or controlled substances to slip within their ... online May 19 in Drug Testing and Analysis , ... contain ingredients other than those claimed and can be hazardous. ...
... obese women with less-than-optimal levels of vitamin D who lose ... increases in circulating levels of this fat-soluble nutrient, according to ... Center. , "Since vitamin D is generally lower in persons ... account, in part, for the link between obesity and diseases ...
... known for years that playing violent video games causes ... a new University of Missouri (MU) study provide one ... video game players become less responsive to violence, and ... "Many researchers have believed that becoming desensitized to ...
Cached Medicine News:Health News:'Guide vests' -- robotic navigation aids for the visually impaired 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 3Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 2Health News:Maryland Stem Cell Research Commission funds 36 new projects in FY 2011 3Health News:Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 2Health News:Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women 3Health News:Violent video games reduce brain response to violence and increase aggressive behavior 2
... The VitalView™ Central Station is ... Criticare bedside monitors for vital signs ... displayed in real time, with simultaneous ... ECG events, graphical and tabular trends ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... Chart Manager provides powerful workflow tools such ... integrated transcription services, and customized flow sheets ... eliminates the need for paper charts. ... a paperless office now and can easily ...
... The Cerner PowerChart Electronic Medical ... solutions designed to create an enterprise-wide, ... (EMR). PowerChart streamlines the workflow process ... access to the functions that support ...
Medicine Products: